Innate Pharma (IPHA) Capital Expenditures (2019 - 2025)
Innate Pharma's (IPHA) quarterly Capital Expenditures came in at -$162966.1 in Q4 2025, up 61.0% YoY from -$101223.6 in Q4 2024, and up 61.0% on a QoQ basis from -$417820.8 in Q4 2024.
Innate Pharma (IPHA) Capital Expenditures (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Capital Expenditures data on file, last reported at -$162966.1 in Q4 2025.
- Quarterly Capital Expenditures rose 61.0% year-over-year to -$162966.1 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.3 million (down 14.47% YoY) and the FY2025 annual result came in at $162966.1, down 61.0% from the prior year.
- Capital Expenditures grew to -$162966.1 in Q4 2025, from -$417820.8 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of -$1067.1 in Q2 2022 to a low of -$1.1 million in Q4 2021.
- A 5-year average of -$327998.4 and a median of -$304759.2 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures soared 98.59% — and 2024, when it sank 9229.06%.
- Tracing IPHA's Capital Expenditures over 5 years: stood at -$1.1 million in 2021, then jumped by 48.64% to -$545832.3 in 2022, then jumped by 30.81% to -$377654.9 in 2023, then dropped by 10.64% to -$417820.8 in 2024, then jumped by 61.0% to -$162966.1 in 2025.
- The last three Capital Expenditures figures came in at -$162966.1 (Q4 2025), -$417820.8 (Q4 2024), and -$304759.2 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 34.68 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.26 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 251.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -73.57 Mn |
| 10 | Innate Pharma | 187.25 Mn | 187.25 Mn | - | -162,966.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -162,966.09 |
| Dec 31, 2025 | -162,966.09 |
| Dec 31, 2024 | -417,820.80 |
| Dec 31, 2024 | -417,820.80 |
| Jun 30, 2024 | -304,759.18 |
| Jun 30, 2024 | -304,759.18 |
| Dec 31, 2023 | -377,654.91 |
| Dec 31, 2023 | -377,654.91 |
| Jun 30, 2023 | -3,266.77 |
| Jun 30, 2023 | -3,266.77 |
| Dec 31, 2022 | -545,832.34 |
| Dec 31, 2022 | -545,832.34 |
| Jun 30, 2022 | -1,067.06 |
| Jun 30, 2022 | -1,067.06 |
| Dec 31, 2021 | -1.06 Mn |
| Dec 31, 2021 | -1.06 Mn |
| Jun 30, 2021 | -75,869.10 |
| Jun 30, 2021 | -75,869.10 |
| Dec 31, 2020 | -1.08 Mn |
| Dec 31, 2020 | -1.08 Mn |